Background

The NIH's K Award, a research career development award, is a support system designed to help clinicians and early-career scientists grow into independent researchers. The K08 primarily supports clinical scientists conducting translational or basic research, while the K23 primarily supports patient-centered researchers who directly interact with patients. Recipients typically dedicate more than 75% of their working time to research and career development activities for 3-5 years, during which they accumulate preliminary data and gain experience as principal investigators, preparing them to apply for independent research grants such as the R01.

Since 2018, the NIH has distinguished between funding opportunities that include and exclude clinical trials. The K Award allowed researchers to either lead small, independent clinical trials or gain research experience by participating in trials led by senior mentors. In particular, for new clinicians who may not be able to handle large-scale confirmatory trials, K Award-supported single-arm studies or feasibility studies provided a rare opportunity to translate ideas into patient research.

However, this pathway has narrowed as the NIH has decided not to support independent clinical trials with K career development awards. This issue is not about the experimental results reported in a paper, but rather about the research funding policy change reported by Science. The approach of combining researcher training and clinical trial execution within a single grant is being reorganized.

Key Findings

The key change is not the elimination of the entire K Award program, but rather the restriction on using K Award funds for recipients to conduct independent clinical trials as principal investigators. This does not mean that observational studies, non-clinical research, and career development activities will be discontinued. The pathway of participating in clinical trials led by senior mentors or co-mentors to gain experience in design and operation should also be considered separately.

The impact may be greater than expected due to the NIH's definition of clinical trials. The NIH defines a clinical trial as a study that prospectively assigns participants to one or more interventions and evaluates health-related biomedical or behavioral outcomes. This includes not only randomized controlled trials of new drugs, but also low-risk behavioral interventions and small, single-arm pilot studies, depending on the circumstances. This represents a significant shift from the existing system, which operated separate funding opportunities that allowed independent trials and separate review criteria for clinical trials.

The K Award provides more than just research funding. It combines protected research time, mentorship, salary, and research support to enable physicians with heavy clinical workloads to establish themselves as researchers. With the removal of the independent trial component, applicants will need to either reframe their research questions as observational studies, join the clinical trials of senior researchers, or seek separate research funding, such as from the R series, simultaneously. Researchers at institutions with limited internal funding are likely to be at a greater disadvantage.

Significance and Prospects

The NIH may interpret this as a measure to concentrate the responsibility for the safety management and operation of clinical trials on researchers with sufficient experience and infrastructure, and to separate career development funding from trial execution funding. Clinical trials involve complex obligations such as registration, data and safety monitoring, statistical planning, and adverse event reporting. There has also been concern that combining research training and patient trials with limited K Award funding may weaken both goals.

On the other hand, concerns have been raised about the loss of opportunities to demonstrate independence. Experience in independently designing and leading recruitment and analysis is an important achievement for subsequent R01 applications and faculty appointments. It may be difficult to demonstrate one's own research agenda and principal investigator capabilities by simply participating in the trials of senior researchers. This may have a greater impact on fields where small pilot studies are central, such as rare diseases, pediatrics, and community research.

The actual impact of the policy will depend on the timing of its implementation, whether existing recipients will continue to receive support, and the composition of funding opportunities and alternative funding sources at individual NIH institutes. If R-series grants or separate early-career researcher programs that support clinical trials are not established, there will be a gap in the career ladder of researchers, from the K Award to the R01.

In the future, alternative models may be considered, such as linking clinical trial operating costs and career development funding in a single review process, or providing conditional support in which institutions provide trial infrastructure.